HOME Research and Development Stem cell and ellular therapies
Research and Development Highlights: Stem cell and cellular therapies
Cord Blood Stem Cell Mesenchymal Stem Cell

Cord Blood Stem Cell (Hematopoietic Stem Cell)

Cell therapy is the inevitable for the 21st century, said Dr. George Daley, Whitehead Institute of Biomedical Research. Since the first in 1988, there have been thousands of successful cord blood transplant cases. Cord blood (hematopoietic stem cell) transplant has been applied to treating blood diseases such as Thalassemia, Leukemia, inherited inefficiency, immune inefficiency, and to post-chemotherapy repairing hematopoietic system.

In order to better serve the purpose of cord blood database multitude, BIONET has established an innovative storage scheme Reciprocity, comprising private banking and public donation model. This scheme entitles all participants to most of the primary rights when enrolling in private banking with considerably less financial burden. For example, they may access to public banking database when in need of searching for matches. The program has been proven successfully responsive as the database of BIONET has grown rapidly, currently holding the fourth position on Bone Marrow Donors Worldwide (BMDW) program. The private database of BIONET is also linked throughout foreign partners like APCBBC.

BIONET core laboratories have been accredited by American Association of Blood Bank (AABB) and Commission on Laboratory Accreditation (COLA). The entire protocol of CBU collecting, screening, processing, cyropreserving, releasing, and discarding, is certifiable for clinical application both domestically and internationally.

It has been a typical long-term deficit in general for the local industries of Taiwan, that the most crucial, fundamental niche of technology is rarely originated locally. Therefore the government has actively promoted supportive programs of encouraging innovative, creative research domestically, and it indeed contributed to accelerate the growth of potential market/technology-driven industries.

BIONET has a solid record of submitting and participating government strategic research projects over the years, audited by Ministry of Economic Affairs, National Science Consolatory, et al. Out of a wide variety of emulation, BIONET has always captured the best provisional and creational trends of the industry and therefore authenticated for its devotion in research as well as reputation.

‧訊聯政府相關單位補助計畫一覽表

政府相關單位補助計畫
執行日期
機關名稱
計畫名稱
2010年 三軍總醫院 臍帶間質幹細胞與乳牙幹細胞輔助傷口修復的效益評估動物實驗—以裸鼠模式測試臍帶間質幹細胞與乳牙幹細胞輔助傷口修復的確效試驗。
2010年 三軍總醫院 Establishment of a traceable mesenchymal stem cell model to track and target primary or metastatic human ovarian cancer cells
建立追蹤及標定人類卵巢癌細胞之可追蹤間質幹細胞模式。
2009年 亞東醫院
台北科技大學
與亞東醫院暨台北科技大學合作爭取國科會產學計畫,以臍帶間質幹細胞(MSC)輔助軟骨再生的臨床前試驗。
2007年 長庚醫院合作 以臍帶間質幹細胞輔助兔子眼角膜細胞修復,並於體外成功培養眼角膜細胞。
2007年 陽明大學
產學合作案
以老鼠為研究對象,將臍帶間質幹細胞與細胞激素應用於傷口修復。
2006年

經濟部
工業局

主導性新商品研究計畫—人類臍帶間質幹細胞及其衍生之應用
‧MSC體內應用:「間質幹細胞與臍帶血共同移植,以治療血液性疾病」。MSC體外應用:「以間質幹細胞為滋養層培養胚胎幹細胞與造血性幹細胞」。

2004年

經濟部
技術處
鼓勵中小企業開發新技術推動計畫—臍帶血多向性間葉(質)幹細胞在移植及組織之技術開發
‧展開臍帶血產業上、中、下游的技術研發及整合;從上游收集技術之改進促使中游細胞處理及加工時得到質量更高的幹細胞,進而提供合作的醫療單位進行臨床試驗。

2003年

經濟部
技術處
鼓勵中小企業開發新技術推動計畫—臍帶血幹細胞免疫分離法之開發研究
‧開發幹細胞免疫分離法,以間質幹細胞之免疫分離為模式系統,評估以專一性抗體作為分離臍帶血幹細胞基礎之可行性。

2003年

國科會
「由人類胎盤分離造血性與多向性幹細胞之最佳化流程研究」
‧開發新的臍帶血收集技術,不僅提高臍帶血的採血量,並增加臍帶/胎盤血中造血性與多向性幹細胞的質與量。

2003年

經濟部
技術處
鼓勵中小企業開發新技術推動計畫—
臍帶血多向性間葉幹細胞應用核心技術的建立
‧ 建立從臍帶血中分離間質幹細胞之技術,並從間質幹細胞誘導分化成似肝細胞(hepatocyte-like cells)。